A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT02722135
- Locations
- 🇧🇪
Boehringer Ingelheim Investigational Site, Gent, Belgium
Fingerprinting of Impulsivity
Completed
- Conditions
- Impulse Control Disorders
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 141
- Registration Number
- NCT02722174
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1
- Registration Number
- NCT02721875
- Locations
- 🇯🇵
University of Fukui Hospital, Fukui, Yoshida-gun, Japan
Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 132
- Registration Number
- NCT02720757
Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)
Completed
- Conditions
- Pulmonary Disease, Chronic ObstructivePulmonary Emphysema
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 463
- Registration Number
- NCT02719184
- Locations
- 🇨🇦
McGill University Health Centre (MUHC), Montreal, Quebec, Canada
🇩🇪Fraunhofer ITEM, Hannover, Germany
🇯🇵Kagoshima University Hospital, Kagoshima, Kagoshima, Japan
OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7443
- Registration Number
- NCT02719639
Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 35
- Registration Number
- NCT02710630
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male Volunteers
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 63
- Registration Number
- NCT02706925
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT02702011
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
🇯🇵Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan
🇯🇵Nishikumamoto Hospital, Kumamoto, Kumamoto, Japan
Capsaicin + Diclofenac Gel in Acute Back Pain or Neck Pain
- First Posted Date
- 2016-03-07
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 746
- Registration Number
- NCT02700815
- Locations
- 🇩🇪
Anästhesiologie Rheinbach, Rheinbach, Germany
🇩🇪Praxis Dr. Schaefer, 45355 Essen, Essen, Germany
🇩🇪Dünnwaldpraxis, Köln, Köln, Germany
© Copyright 2025. All Rights Reserved by MedPath